Cited by — Severe Interstitial Lung Disease With First‐Line Enfortumab Vedotin Plus Pembrolizumab in Japanese Real‐World Practice | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Severe Interstitial Lung Disease With First‐Line Enfortumab Vedotin Plus Pembrolizumab in Japanese Real‐World Practice.
No admitted local citation edges point to this work yet.
